Alpha Tau Medical Ltd Cl A (DRTS)

$6.86 -0.04 (-0.58%)
Market Cap 581.87M
Revenue (ttm) 0.00
Net Income (ttm) -42.63M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.08
Volume 236,300
Avg Vol 325,470
Day's Range N/A - N/A
Shares Out 84.82M
Stochastic %K 24%
Beta 1.02
Analysts Sell
Price Target $9.67

Company Profile

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical or pending clinical studies for brain and other cancers. The company is headquartered in Jerusalem, Israel.

Industry: Biotechnology
Sector: Healthcare
Phone: 972 3 577 4115
Address:
Kiryat HaMada St. 5, Jerusalem, Israel
Jessypenny
Jessypenny Mar. 30 at 7:08 AM
$DRTS Watching the chart closely this week. People seem to be overlooking the Alpha DaRT tech while it's sitting under $7. With major readouts coming up for pancreatic and skin cancer, this level feels like a massive mispricing.
0 · Reply
ScopeChartTeam
ScopeChartTeam Mar. 30 at 5:11 AM
$DRTS looks active, just observing.
0 · Reply
JohnStocksNY
JohnStocksNY Mar. 29 at 1:26 PM
$DRTS Market closed? Alpha Tau still hard at work and successfully so!
0 · Reply
Jessypenny
Jessypenny Mar. 29 at 9:02 AM
4 stocks om watching closely this week: $TLYS The March leader (+196%!). Looking to see if this retail momentum carries over or if we get a healthy pullback for a fresh entry. $DRTS Consolidating near $7 after a strong move. Watching for a break through that $8 wall to ignite the run toward $10. things can move fast with the announcement about Q1 Recruitment Finish for U.S. Pancreatic Cancer (IMPACT) and ReSTART Skin Cancer trials $SLS AACR data is imminent. With the REGAL trial nearing its final events and a recent earnings beat, the $4.40 support is the floor before the next leg up. $SOC Energy is heating up and this one is riding the wave (+114% this month). Watching for a breakout above $18.50 to keep the trend alive.
1 · Reply
Jessypenny
Jessypenny Mar. 29 at 8:09 AM
$DRTS And we should be getting some great news about a couple of the in the very near future
3 · Reply
Joshsim123
Joshsim123 Mar. 29 at 8:04 AM
$DRTS is effectively a commercial-stage company with five lottery tickets in the most lucrative and high-unmet-need oncology markets (Brain, Lung, Pancreas, Prostate, and Skin).
1 · Reply
JohnStocksNY
JohnStocksNY Mar. 29 at 7:59 AM
$DRTS If you don’t believe me or aren’t excited just read the Stocktwits summary
1 · Reply
kareem1988
kareem1988 Mar. 29 at 7:46 AM
$DRTS Has me so excited: Q1 Recruitment Finish Line: We are in the final days of March, meaning the official update on the completion of patient recruitment for the U.S. Pancreatic Cancer (IMPACT) and ReSTART Skin Cancer trials is imminent. DDW 2026 (May 2-5) Digestive Disease Week is right around the corner. After those killer results at ASCO GI in January (81% disease control rate!), the market is expecting more data deep-dives here.
2 · Reply
Jordan3333
Jordan3333 Mar. 29 at 7:30 AM
$DRTS I’m losing big on everything I own, $DRTS is holding and when this market stabilizes, it should move up nicely
2 · Reply
JohnStocksNY
JohnStocksNY Mar. 29 at 7:24 AM
$DRTS is #1 and now with an icon. You love to see it!
1 · Reply
Latest News on DRTS
Alpha Tau Medical: 2026 Is The Breakthrough Year

Mar 24, 2026, 12:31 AM EDT - 6 days ago

Alpha Tau Medical: 2026 Is The Breakthrough Year

Alpha Tau to Present at Sidoti March Virtual Small Cap Conference

Mar 16, 2026, 10:02 AM EDT - 13 days ago

Alpha Tau to Present at Sidoti March Virtual Small Cap Conference

Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update

Mar 9, 2026, 4:02 PM EDT - 20 days ago

Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update

HekaBio and Alpha Tau Medical Obtain Approval in Japan for Solid Tumor Treatment Alpha DaRT

Feb 24, 2026, 8:51 PM EST - 4 weeks ago

HekaBio and Alpha Tau Medical Obtain Approval in Japan for Solid Tumor Treatment Alpha DaRT

Alpha Tau Medical Receives Japanese Marketing Approval for Alpha DaRT® in Unresectable Locally Advanced or Locally Recurrent Head and Neck Cancer

Feb 24, 2026, 9:00 AM EST - 4 weeks ago

Alpha Tau Medical Receives Japanese Marketing Approval for Alpha DaRT® in Unresectable Locally Advanced or Locally Recurrent Head and Neck Cancer

Altamirano PLLC Issues Investor Notice on Inspired Healthcare Capital (IHC) Chapter 11 Bankruptcy Filing

Feb 3, 2026, 12:37 PM EST - 7 weeks ago

Altamirano PLLC Issues Investor Notice on Inspired Healthcare Capital (IHC) Chapter 11 Bankruptcy Filing

Alpha Tau Issues Letter to Shareholders: Five Concurrent Trials in the U.S. with Multiple Significant Value-Driving Milestones Ahead

Jan 29, 2026, 9:00 AM EST - 2 months ago

Alpha Tau Issues Letter to Shareholders: Five Concurrent Trials in the U.S. with Multiple Significant Value-Driving Milestones Ahead

Alpha Tau Medical: Pancreatic, GBM, And Other Updates; Set Up For A Strong, Catalyst-Rich 2026

Jan 23, 2026, 3:34 AM EST - 2 months ago

Alpha Tau Medical: Pancreatic, GBM, And Other Updates; Set Up For A Strong, Catalyst-Rich 2026

Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Symposium Showcasing Immune-Preservation and High Disease Control in Montreal Pancreatic Cancer Alpha DaRT® Study

Jan 6, 2026, 9:00 AM EST - 2 months ago

Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Symposium Showcasing Immune-Preservation and High Disease Control in Montreal Pancreatic Cancer Alpha DaRT® Study

Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT® for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC)

Jan 5, 2026, 9:00 AM EST - 2 months ago

Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT® for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC)

Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State University

Dec 9, 2025, 9:00 AM EST - 3 months ago

Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State University

Alpha Tau Announces Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 20, 2025, 4:05 PM EST - 4 months ago

Alpha Tau Announces Third Quarter 2025 Financial Results and Provides Corporate Update

Alpha Tau to Participate at Jefferies Global Healthcare Conference in London

Nov 11, 2025, 8:30 AM EST - 4 months ago

Alpha Tau to Participate at Jefferies Global Healthcare Conference in London

Alpha Tau Announces Receipt of Radioactive Material License for its New Hampshire Manufacturing Facility, Advancing Towards Commercial Readiness

Oct 21, 2025, 8:30 AM EDT - 5 months ago

Alpha Tau Announces Receipt of Radioactive Material License for its New Hampshire Manufacturing Facility, Advancing Towards Commercial Readiness

Altamirano PLLC Issues Notice to Inspired Healthcare Capital (IHC) Investors on Recovery Options

Oct 17, 2025, 10:04 AM EDT - 5 months ago

Altamirano PLLC Issues Notice to Inspired Healthcare Capital (IHC) Investors on Recovery Options

Alpha Tau Medical: Localized Alpha Radiation, A New Paradigm In Oncology

Oct 16, 2025, 11:55 AM EDT - 5 months ago

Alpha Tau Medical: Localized Alpha Radiation, A New Paradigm In Oncology

Alpha Tau Successfully Treats First Patient in its U.S. Multi-Center Pancreatic Cancer Clinical Trial

Sep 2, 2025, 8:30 AM EDT - 7 months ago

Alpha Tau Successfully Treats First Patient in its U.S. Multi-Center Pancreatic Cancer Clinical Trial

Alpha Tau to Participate in Five September Investor Conferences

Aug 27, 2025, 8:30 AM EDT - 7 months ago

Alpha Tau to Participate in Five September Investor Conferences

Alpha Tau Announces Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 11, 2025, 4:02 PM EDT - 8 months ago

Alpha Tau Announces Second Quarter 2025 Financial Results and Provides Corporate Update

Revival Healthcare Capital Announces Strategic Partnership to Accelerate External Innovation in Robotics With up to $458 Million Joint Investment With Olympus Into Co-Founded New Company Swan EndoSurgical

Jul 25, 2025, 9:04 AM EDT - 8 months ago

Revival Healthcare Capital Announces Strategic Partnership to Accelerate External Innovation in Robotics With up to $458 Million Joint Investment With Olympus Into Co-Founded New Company Swan EndoSurgical

Alpha Tau Announces First Quarter 2025 Financial Results and Provides Corporate Update

May 19, 2025, 4:01 PM EDT - 11 months ago

Alpha Tau Announces First Quarter 2025 Financial Results and Provides Corporate Update

Alpha Tau Announces Appointment of Nadav Kidron to its Board of Directors

May 12, 2025, 4:01 PM EDT - 11 months ago

Alpha Tau Announces Appointment of Nadav Kidron to its Board of Directors

Alpha Tau to Participate in May Investor Conferences

May 6, 2025, 8:30 AM EDT - 11 months ago

Alpha Tau to Participate in May Investor Conferences

Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals

Apr 28, 2025, 9:00 AM EDT - 11 months ago

Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals

ORMP

Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical

Apr 28, 2025, 9:00 AM EDT - 11 months ago

Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical

ORMP

Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma

Apr 2, 2025, 8:30 AM EDT - 1 year ago

Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma

Alpha Tau Announces Full Year 2024 Financial Results and Provides Corporate Update

Mar 12, 2025, 4:02 PM EDT - 1 year ago

Alpha Tau Announces Full Year 2024 Financial Results and Provides Corporate Update

Alpha Tau Receives Medical Device Single Audit Program (MDSAP) Certification

Feb 24, 2025, 8:30 AM EST - 1 year ago

Alpha Tau Receives Medical Device Single Audit Program (MDSAP) Certification

Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day

Jan 27, 2025, 9:00 AM EST - 1 year ago

Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day

Alpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&D Update Day

Dec 18, 2024, 8:30 AM EST - 1 year ago

Alpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&D Update Day

Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor

Dec 17, 2024, 9:00 AM EST - 1 year ago

Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor

Alpha Tau to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 11, 2024, 8:30 AM EST - 1 year ago

Alpha Tau to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Alpha Tau to Participate in Ladenburg's Oncology Innovators & Investors Symposium

Dec 6, 2024, 8:30 AM EST - 1 year ago

Alpha Tau to Participate in Ladenburg's Oncology Innovators & Investors Symposium

Alpha Tau to Participate in Citi's 2024 Global Healthcare Conference and Piper Sandler's 36th Annual Healthcare Conference

Nov 13, 2024, 8:30 AM EST - 1 year ago

Alpha Tau to Participate in Citi's 2024 Global Healthcare Conference and Piper Sandler's 36th Annual Healthcare Conference

Alpha Tau Announces Acceptance Into FDA's Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma Multiforme

Oct 21, 2024, 8:30 AM EDT - 1 year ago

Alpha Tau Announces Acceptance Into FDA's Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma Multiforme

Alpha Tau Treats First Patient with Recurrent Lung Cancer

Oct 10, 2024, 8:30 AM EDT - 1 year ago

Alpha Tau Treats First Patient with Recurrent Lung Cancer

Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Investigator-Initiated Study of Alpha DaRT® in Immunocompromised Patients with Recurrent cSCC

Sep 20, 2024, 8:30 AM EDT - 1 year ago

Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Investigator-Initiated Study of Alpha DaRT® in Immunocompromised Patients with Recurrent cSCC

Alpha Tau to Participate in the H.C. Wainwright 26th Annual Global Investment Conference, the Sidoti Small-Cap Virtual Investor Conference, the Redburn Atlantic and Rothschild & Co 2024 Radiopharma Conference, and the Lytham Partners Fall 2024 Investor Conference

Aug 22, 2024, 8:30 AM EDT - 1 year ago

Alpha Tau to Participate in the H.C. Wainwright 26th Annual Global Investment Conference, the Sidoti Small-Cap Virtual Investor Conference, the Redburn Atlantic and Rothschild & Co 2024 Radiopharma Conference, and the Lytham Partners Fall 2024 Investor Conference

Alpha Tau Medical Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 14, 2024, 4:02 PM EDT - 1 year ago

Alpha Tau Medical Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Alpha Tau Announces Publication in Cancers Journal of Long-Term Safety and Efficacy Data in Multiple Hard-to-Treat Superficial Cancers

Jun 25, 2024, 8:30 AM EDT - 1 year ago

Alpha Tau Announces Publication in Cancers Journal of Long-Term Safety and Efficacy Data in Multiple Hard-to-Treat Superficial Cancers

Alpha Tau to Present at the Jefferies Global Healthcare Conference

May 21, 2024, 8:45 AM EDT - 2 years ago

Alpha Tau to Present at the Jefferies Global Healthcare Conference

Alpha Tau Medical Announces First Quarter 2024 Financial Results and Provides Corporate Update

May 20, 2024, 4:01 PM EDT - 2 years ago

Alpha Tau Medical Announces First Quarter 2024 Financial Results and Provides Corporate Update

Alpha Tau Announces Alpha DaRT Treatment of First Patient with Liver Metastases of Colorectal Cancer

May 13, 2024, 8:30 AM EDT - 2 years ago

Alpha Tau Announces Alpha DaRT Treatment of First Patient with Liver Metastases of Colorectal Cancer

Alpha Tau Presents Preclinical Data Demonstrating Abscopal Immune Effect in Pancreatic Murine Tumor Models at ESTRO 2024 Congress in Glasgow

May 6, 2024, 8:30 AM EDT - 2 years ago

Alpha Tau Presents Preclinical Data Demonstrating Abscopal Immune Effect in Pancreatic Murine Tumor Models at ESTRO 2024 Congress in Glasgow

Alpha Tau to Present at the Jefferies Radiopharma Innovation Summit

Mar 25, 2024, 8:50 AM EDT - 2 years ago

Alpha Tau to Present at the Jefferies Radiopharma Innovation Summit

Alpha Tau Medical Announces Full Year 2023 Financial Results and Provides Corporate Update

Mar 7, 2024, 4:01 PM EST - 2 years ago

Alpha Tau Medical Announces Full Year 2023 Financial Results and Provides Corporate Update

Alpha Tau to Participate in Barclays 26th Annual Global Healthcare Conference

Feb 26, 2024, 8:30 AM EST - 2 years ago

Alpha Tau to Participate in Barclays 26th Annual Global Healthcare Conference

Alpha Tau to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 20, 2023, 9:15 AM EST - 2 years ago

Alpha Tau to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Alpha Tau to Participate in Sidoti Small-Cap Conference

Nov 29, 2023, 8:30 AM EST - 2 years ago

Alpha Tau to Participate in Sidoti Small-Cap Conference

Alpha Tau Announces Highly Promising Interim Results from Safety and Feasibility Trial of Alpha DaRT Treatment of Advanced Pancreatic Cancer

Nov 28, 2023, 8:30 AM EST - 2 years ago

Alpha Tau Announces Highly Promising Interim Results from Safety and Feasibility Trial of Alpha DaRT Treatment of Advanced Pancreatic Cancer

Jessypenny
Jessypenny Mar. 30 at 7:08 AM
$DRTS Watching the chart closely this week. People seem to be overlooking the Alpha DaRT tech while it's sitting under $7. With major readouts coming up for pancreatic and skin cancer, this level feels like a massive mispricing.
0 · Reply
ScopeChartTeam
ScopeChartTeam Mar. 30 at 5:11 AM
$DRTS looks active, just observing.
0 · Reply
JohnStocksNY
JohnStocksNY Mar. 29 at 1:26 PM
$DRTS Market closed? Alpha Tau still hard at work and successfully so!
0 · Reply
Jessypenny
Jessypenny Mar. 29 at 9:02 AM
4 stocks om watching closely this week: $TLYS The March leader (+196%!). Looking to see if this retail momentum carries over or if we get a healthy pullback for a fresh entry. $DRTS Consolidating near $7 after a strong move. Watching for a break through that $8 wall to ignite the run toward $10. things can move fast with the announcement about Q1 Recruitment Finish for U.S. Pancreatic Cancer (IMPACT) and ReSTART Skin Cancer trials $SLS AACR data is imminent. With the REGAL trial nearing its final events and a recent earnings beat, the $4.40 support is the floor before the next leg up. $SOC Energy is heating up and this one is riding the wave (+114% this month). Watching for a breakout above $18.50 to keep the trend alive.
1 · Reply
Jessypenny
Jessypenny Mar. 29 at 8:09 AM
$DRTS And we should be getting some great news about a couple of the in the very near future
3 · Reply
Joshsim123
Joshsim123 Mar. 29 at 8:04 AM
$DRTS is effectively a commercial-stage company with five lottery tickets in the most lucrative and high-unmet-need oncology markets (Brain, Lung, Pancreas, Prostate, and Skin).
1 · Reply
JohnStocksNY
JohnStocksNY Mar. 29 at 7:59 AM
$DRTS If you don’t believe me or aren’t excited just read the Stocktwits summary
1 · Reply
kareem1988
kareem1988 Mar. 29 at 7:46 AM
$DRTS Has me so excited: Q1 Recruitment Finish Line: We are in the final days of March, meaning the official update on the completion of patient recruitment for the U.S. Pancreatic Cancer (IMPACT) and ReSTART Skin Cancer trials is imminent. DDW 2026 (May 2-5) Digestive Disease Week is right around the corner. After those killer results at ASCO GI in January (81% disease control rate!), the market is expecting more data deep-dives here.
2 · Reply
Jordan3333
Jordan3333 Mar. 29 at 7:30 AM
$DRTS I’m losing big on everything I own, $DRTS is holding and when this market stabilizes, it should move up nicely
2 · Reply
JohnStocksNY
JohnStocksNY Mar. 29 at 7:24 AM
$DRTS is #1 and now with an icon. You love to see it!
1 · Reply
JohnStocksNY
JohnStocksNY Mar. 29 at 7:16 AM
$DRTS Some early trending, this community doesn’t sleep! You probably shouldn’t sleep on Alpha Tau either
3 · Reply
Jessypenny
Jessypenny Mar. 29 at 7:07 AM
$DRTS continues to show incredible strength. While the broader sector has been choppy, we’re seeing a very healthy consolidation floor. Volume is slowly increasing and $DRTS is getting ready to pop. Don’t sleep on the stability here.
2 · Reply
JohnStocksNY
JohnStocksNY Mar. 28 at 8:54 PM
$DRTS We finally got an icon for the stock!
1 · Reply
JohnStocksNY
JohnStocksNY Mar. 28 at 8:53 PM
$DRTS Love being part of this journey
1 · Reply
RadioIsotope25
RadioIsotope25 Mar. 28 at 1:42 PM
Radiopharm Theranostics (ASX: RAD) Investor Webinar -- RAD 101 Phase 2b second interim data - Zoom $RADX $ARTL $DRTS $IMNM https://us02web.zoom.us/rec/play/jHo4QT2d91u1IuLLzNdkfW7O01zHB8XV7X4-USlV2y-4TPZFkHt4U3BZJIlXY9cRVVMI-WgS-3Ji3Rtg.dh4n_6T8eCGOud-B
3 · Reply
Growthataresonablecost
Growthataresonablecost Mar. 27 at 6:42 PM
$DRTS One of my only stocks that is Green today!
1 · Reply
SlimyMango
SlimyMango Mar. 27 at 3:51 PM
$DRTS
3 · Reply
JohnStocksNY
JohnStocksNY Mar. 27 at 2:03 PM
$DRTS I’m telling you don’t let the macro fool you. People will be looking back this year and won’t believe they could’ve bought at these prices. Take a peek at what’s coming and you won’t want any other stock but this one.
2 · Reply
Jessypenny
Jessypenny Mar. 26 at 6:46 PM
Very interesting post from $DRTS reddit sub: Merck's $6.7B Oncology Acquisition and the Repricing of Cancer M&A https://www.reddit.com/r/DRTS_Stock/s/tlluYrsG49
1 · Reply
Herbgator
Herbgator Mar. 26 at 5:15 PM
$DRTS https://x.com/alphatauinsight/status/2037215080564039907?s=46
2 · Reply
Herbgator
Herbgator Mar. 26 at 5:13 PM
$DRTS I’m loving this in conjunction with the upcoming conference in Chicago on May 2. A lot of excitement in the Pancreatic indication near term!
2 · Reply
JohnStocksNY
JohnStocksNY Mar. 26 at 2:15 PM
$DRTS Still can’t find this anywhere, it’s like this company is doing its best to be under the radar
2 · Reply